The company has several ongoing development projects that apply the company’s widely patented GTU® technology. The company reported of its development projects in the offering circular published on May 29, 2015 in connection with the initial public offering. Of these projects, the treatment vaccine against bovine papilloma virus and Ebola did not meet the targets of the company. Said genetic vaccines projects have been discontinued and the suitability of said drug candidates for gene-based treatments is being examined. On January 7, 2016, the company announced the composition of its development project portfolio, and the portfolio currently comprises the following projects:
1. GTU® gene therapy
In gene therapy, the aim is to transport the desired genes to human somatic cells where they start to produce therapeutic or preventive proteins. The company is presently conducting preclinical studies to obtain proof-of-concept for the patented GTU® technology in gene therapy.
2. GTU® genetic vaccines
With its GTU® vaccines, the company focuses particularly on the prevention and treatment of diseases in areas where treatments do not exist at the moment, or where medical treatments have poor efficacy or safety. Examples of such areas are tuberculosis, HIV and certain animal infectious diseases.
3. Research collaboration
Besides direct license agreements, the company aims to enter research agreements as a stepping stone for final licence agreements. The company is a member of the EU Horizon 2020 research consortium developing a new type of treatment for HIV. The company manufactures the test vaccines in its own production facility.